The Translational Research Initiative for Hearing (TRIH) Grant helps move research closer to patients. The grant is international. We fund applied research projects at research institutes and small to medium enterprises (SMEs) across the world. This year, Fondation Pour l’Audition and Action on Hearing Loss are partnering to co-fund the TRIH grant.
The TRIH Grant supports:
- research with strong commercial potential, likely to attract follow-on funding at the conclusion of the grant.
- studies that will facilitate and enable the progression of promising basic research towards testing in clinical trials.
The TRIH Grant does not support basic research into the causes and underpinning biology of hearing loss and tinnitus or the development of devices or software.
2020 TRIH Grant
- Duration: up to three years
- Eligibility: applicants may be from any country and may be from academic institutions and small/medium enterprises (SMEs)
- Value: Up to £100,000 per year
- expression of interest: 14 April 2020 (5pm GMT)
- full application (by invitation only): 12 June 2020 (5pm GMT)
- funding decisions: November/December 2020
First, an expression of interest must be submitted. This gives us enough information about the proposed project to understand how well it aligns with the requirements and eligibility of the TRIH scheme.
Applicants whose proposals meet the criteria of the scheme are then invited to submit a full application.
This year, the scope of the Translational Research Initiative for Hearing call includes : Small molecule, gene or cell-based approaches for the treatment of hearing loss or tinnitus.
Applications can include:
- studies which will enable lead optimisation and/or candidate selection
Pharmacodynamics (PKPD) studies
- safety/toxicology studies
- drug repositioning/repurposing (applications must contain preliminary data supporting the proposed approach)
- validation of therapeutic targets for the treatment of hearing loss or tinnitus (applications must contain preliminary data supporting the proposed approach)
- studies to strengthen confidence that a target or therapeutic approach will be applicable to human hearing loss or tinnitus
- identification/validation of methods or outcomes that could be used for one or more of the following*:
- patient selection/stratification for clinical trials
- robust measurement of treatment responses in clinical trials.
*Please note that these studies must support the development of a specific therapeutic. General research into outcome measures not aligned to a specific therapeutic should be submitted to other grant schemes of FondationPour l'Audition (call for laboratories) and Action on Hearing Loss (i.e Discovery Research Grant Scheme).
Areas in which applications will NOT be accepted:
- basic research into the causes and underpinning biology of hearing loss and tinnitus
- the development of devices or software
- the optimisation of current clinical protocols
- health service studies.
How to applyGo to https://www.
For more information: email@example.com